Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
作者信息
Schulze-Koops Hendrik
机构信息
Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University of Munich, Munich, Germany.
出版信息
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv1-iv3. doi: 10.1093/rheumatology/kex275.
Abstract
摘要
相似文献
1
Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.满足未满足的临床需求：生物类似药在治疗风湿性疾病中的潜力。
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv1-iv3. doi: 10.1093/rheumatology/kex275.
2
Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.墨西哥生物类似药的现状：墨西哥风湿病学会的立场，2016年
Reumatol Clin (Engl Ed). 2018 May-Jun;14(3):127-136. doi: 10.1016/j.reuma.2017.07.002. Epub 2017 Aug 12.
3
Biosimilar monoclonal antibodies: preclinical and clinical development aspects.生物类似单克隆抗体：临床前和临床开发方面
Clin Exp Rheumatol. 2016 Jul-Aug;34(4):698-705. Epub 2016 Jul 4.
4
[Biosimilars].[生物类似药]
Z Rheumatol. 2015 Oct;74(8):670-1. doi: 10.1007/s00393-014-1490-0.
5
[Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
Z Rheumatol. 2014 Sep;73(7):676.
6
An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.FDA 视角下的风湿免疫治疗用拟生物药品的评估。
Nat Rev Rheumatol. 2017 Feb;13(2):123-128. doi: 10.1038/nrrheum.2016.204. Epub 2017 Jan 5.
7
[Biosimilars in rheumatology. Development and results of clinical trials].[风湿病学中的生物类似药。临床试验的开展与结果]
Z Rheumatol. 2015 Oct;74(8):682-8. doi: 10.1007/s00393-014-1487-8.
8
Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).生物类似药：一个机遇。法国风湿病学会（SFR）和炎性风湿病俱乐部（CRI）的立场声明。
Joint Bone Spine. 2018 Jul;85(4):399-402. doi: 10.1016/j.jbspin.2018.03.002. Epub 2018 Mar 21.
9
Biosimilars in childhood chronic rheumatic diseases: friend or foe?
Lancet Rheumatol. 2024 Jul;6(7):e413-e414. doi: 10.1016/S2665-9913(24)00127-9. Epub 2024 Jun 3.
10
A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.风湿性疾病中生物类似药英夫利昔单抗（CT-P13）的科学进展
Expert Rev Clin Immunol. 2015;11 Suppl 1:S1-4. doi: 10.1586/1744666X.2015.1090876.
引用本文的文献
1
[Revised version of the statement by the DGRh on biosimilars-update 2017].[德国风湿病学会（DGRh）关于生物类似药的声明修订版 - 2017年更新]
Z Rheumatol. 2018 Feb;77(1):81-90. doi: 10.1007/s00393-017-0407-0.
本文引用的文献
1
The road from development to approval: evaluating the body of evidence to confirm biosimilarity.从研发到获批之路：评估用以确认生物相似性的证据体系。
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv4-iv13. doi: 10.1093/rheumatology/kex279.
2
The process defines the product: what really matters in biosimilar design and production?该过程定义了产品：生物类似药设计与生产中真正重要的是什么？
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv14-iv29. doi: 10.1093/rheumatology/kex278.
3
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.风湿病领域的生物类似药：证据综述及其在治疗方案中的地位
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv30-iv48. doi: 10.1093/rheumatology/kex277.
4
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.审视生物类似药的证据：关键见解、经验教训与未来展望。
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv49-iv62. doi: 10.1093/rheumatology/kex276.
5
Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.银屑病关节炎的药物治疗：2015 年更新版 EULAR 银屑病关节炎管理建议的系统文献回顾。
Ann Rheum Dis. 2016 Mar;75(3):490-8. doi: 10.1136/annrheumdis-2015-208466. Epub 2015 Dec 11.
6
Biosimilars for the management of rheumatoid arthritis: economic considerations.用于类风湿性关节炎治疗的生物类似药：经济考量
Expert Rev Clin Immunol. 2015;11 Suppl 1:S43-52. doi: 10.1586/1744666X.2015.1090313.
7
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.六种中东欧国家治疗类风湿关节炎的生物类似药英夫利昔单抗（CT-P13）的预算影响分析。
Eur J Health Econ. 2014 May;15 Suppl 1(Suppl 1):S65-71. doi: 10.1007/s10198-014-0595-3. Epub 2014 May 16.
8
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.2012年英国风湿病学会（BSR）和英国风湿病与康复协会（BHPR）关于使用生物制剂治疗银屑病关节炎的指南。
Rheumatology (Oxford). 2013 Oct;52(10):1754-7. doi: 10.1093/rheumatology/ket187. Epub 2013 Jul 25.
9
The role of biosimilars in the treatment of rheumatic diseases.生物类似药在风湿性疾病治疗中的作用。
Ann Rheum Dis. 2013 Mar;72(3):322-8. doi: 10.1136/annrheumdis-2012-202715. Epub 2012 Dec 19.
10
Update on biologic therapies in ankylosing spondylitis: a literature review.生物制剂治疗强直性脊柱炎的研究进展：文献综述
Int J Rheum Dis. 2012 Oct;15(5):445-54. doi: 10.1111/j.1756-185X.2012.01765.x. Epub 2012 Jul 9.
Zotero 插件